Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) Shares Outstanding (Weighted Average): 2022-2024

Historic Shares Outstanding (Weighted Average) for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Dec 2024 value amounting to $38.0 million.

  • Orchestra BioMed Holdings' Shares Outstanding (Weighted Average) rose 42.65% to $54.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.0 million, marking a year-over-year increase of 42.65%. This contributed to the annual value of $38.0 million for FY2024, which is 6.35% up from last year.
  • According to the latest figures from FY2024, Orchestra BioMed Holdings' Shares Outstanding (Weighted Average) is $38.0 million, which was up 6.35% from $35.7 million recorded in FY2023.
  • In the past 5 years, Orchestra BioMed Holdings' Shares Outstanding (Weighted Average) ranged from a high of $38.0 million in FY2024 and a low of $30.6 million during FY2022.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $34.8 million, with a median of $35.7 million in 2023.
  • Data for Orchestra BioMed Holdings' Shares Outstanding (Weighted Average) shows a peak YoY grew of 16.69% (in 2023) over the last 5 years.
  • Over the past 3 years, Orchestra BioMed Holdings' Shares Outstanding (Weighted Average) (Yearly) stood at $30.6 million in 2022, then grew by 16.69% to $35.7 million in 2023, then climbed by 6.35% to $38.0 million in 2024.